

UNIVERSITÀ DEGLI STUDI DI MILANO

selezione pubblica per n. 1 posto/i di Ricercatore a tempo determinato ai sensi dell'art.24, comma 3, lettera b) della Legge 240/2010 per il settore concorsuale 06/D3 - Malattie del Sangue, Oncologia e Reumatologia

settore scientifico-disciplinare MED/06 - Oncologia Medica

presso il Dipartimento di ONCOLOGIA ED EMATO-ONCOLOGIA

(avviso bando pubblicato sulla G.U. n. 68 del 01/09/2020) Codice concorso 4456

Elisabetta Munzone

## CURRICULUM VITAE

### INFORMAZIONI PERSONALI

COGNOME	Munzone
NOME	Elisabetta
DATA DI NASCITA	20 Febbraio 1966

### POSIZIONE LAVORATIVA ATTUALE

2017 - Oggi	Dirigente Medico con Incarico di Alta Specializzazione quale Referente per Innovazioni terapeutiche nel carcinoma mammario avanzato, Divisione di Senologia Medica, presso l'Istituto Europeo di Oncologia, Milano
2011 - Oggi	Vice Direttore Senior, Divisione di Senologia Medica, presso l'Istituto Europeo di Oncologia, Milano

### FORMAZIONE

1984	Diploma di Maturità Scientifica, presso il Liceo Scientifico Statale Omnicomprensivo di San Donato Milanese (MI)
1990	Laurea in Medicina e Chirurgia, con pieni voti assoluti e lode, presso l'Università degli Studi di Milano, Milano
1991	Abilitazione all'Esercizio della professione di Medico Chirurgo
1994	Specializzazione in Oncologia, con pieni voti assoluti, presso l'Università degli Studi di Milano, Milano
2009	Guest Researcher, National Cancer Institute, Bethesda, MD, USA
2017	Immissione in ruolo e equiparazione dei titoli e dei servizi a SSN ai sensi dell'art. 15 undecies del d.lgs. n. 502/92 e s.m.i. del vigente Regolamento, a seguito del Concorso in sanatoria per Dirigente medico presso Istituto Europeo di Oncologia, Milano
2019	Attestato Partecipazione Corso "Oncologie Italiane d'Eccellenza" Programmi Formativi Executive, presso SDA Bocconi School of Management, Milano

## PRECEDENTI POSIZIONI E ATTIVITA' CLINICO-ASSISTENZIALE

2007 - 2011	Vice Direttore, Divisione di Oncologia Medica, presso l'Istituto Europeo di Oncologia, Milano
2001 - 2007	Assistente Senior, Divisione di Oncologia Medica, presso l'Istituto Europeo di Oncologia, Milano
1996 - 2001	Assistente, Divisione di Oncologia Medica, presso l'Istituto Europeo di Oncologia, Milano
1995 - 1996	Borsista, Divisione di Oncologia Medica, presso l'Istituto Europeo di Oncologia, Milano
1991 - 1995	Borsista in formazione, Divisione di Oncologia Medica A, Istituto Nazionale Tumori, Milano

## Competenze Cliniche e di Ricerca Clinica

La Dott.ssa Elisabetta Munzone svolge la sua attività clinica e di ricerca concentrandosi soprattutto sui nuovi trattamenti e sui nuovi approcci terapeutici con terapie biologiche e mirate nelle donne affette da neoplasia mammaria, con particolare attenzione all'identificazione di fenotipi specifici sulla base di una caratterizzazione patologica, clinica, genetica e molecolare al fine di personalizzare i trattamenti.

Nel ruolo che ricopre all'interno della Divisione di Senologia Medica, IEO, la Dott.ssa Munzone ha competenze specifiche, funzionali e professionali specialistiche e autonome rivolte alla gestione e al trattamento di pazienti affette da carcinoma mammario.

E' un medico referente per il paziente sia per gli aspetti clinici sia relazionali.

Assicura la corretta realizzazione dell'attività clinica, la gestione dei casi affidati e la supervisione del lavoro degli assistenti.

Propone miglioramenti ai protocolli interni e ai processi organizzativi, secondo le linee guida definite internamente.

Collabora al raggiungimento di un elevato livello di soddisfazione del paziente garantendo un'elevata qualità terapeutica e relazionale, e garantendo un elevato livello di assistenza nei confronti del paziente.

Si impegna nella proposta di tematiche di interesse per l'Istituto e gestisce lo sviluppo delle fasi operative di attività di ricerca clinica per la gestione dei dati e della documentazione, per l'analisi delle informazioni provenienti dalla sua attività e per gli altri colleghi.

Gestisce autonomamente la pubblicazione e la presentazione dei lavori scientifici.

Collabora allo sviluppo della visibilità interno e al di fuori della sua divisione, partecipando a task force e gruppi nazionali e internazionali o gruppi di lavoro multi-centrici, mantenendo le relazioni e gli scambi nella comunità professionale e scientifica.

E' Principal Investigator (PI) o co-PI di diversi studi clinici rivolti a donne con carcinoma mammario nell'ambito dei trattamenti adiuvanti, neoadiuvanti e per la malattia metastatica. Alcuni di questi sono dedicati allo studio dei trattamenti metronomici ed hanno come obiettivo lo sviluppo di trattamenti innovativi con basso profilo di tossicità nel rispetto della qualità della vita delle pazienti.

In collaborazione con ricercatori di base, ha coordinato studi correlativi e traslazionali con particolare interesse al processo di formazione delle metastasi cerebrali nell'ambito del carcinoma mammario.

Coordina studi che stanno valutando la combinazione di nuovi agenti, comprese le nuove formulazioni di chemioterapia e di terapia ormonale per donne affette da carcinoma mammario.

- PI dello Studio METEORA: "MEtronomic TrEatment Option in advanced bReast cAnceR: A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) versus weekly paclitaxel as first-line or second-line treatment in patients with ER-positive/HER2-negative advanced or metastatic breast cancer"  
Coordinato da IBCSG, pazienti previsti 160.
- PI dello Studio POLAR: "Palbociclib for HR+ Isolated Local or Regional Recurrence of Breast Cancer: A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected locoregional recurrence of breast cancer"  
Coordinato da IBCSG e BIG, pazienti previsti 450
- PI dello Studio FACILE: "FeAsibility of first-line riboCiclib in oLdEr patients with advanced breast cancer. Phase II, multicenter, single arm trial to assess the feasibility of first line ribociclib in combination with a non steroidal aromatase inhibitor in elderly patients with hormone receptor positive/HER2 negative advanced breast cancer".  
Coordinato da Fondazione Sandro Pitigliani, pazienti previsti 196

## ATTIVITA' DI RICERCA

### *Responsabilità di progetti finanziati su base competitiva*

2017 - 2020	H2020-SC1-2016-2017 coordinatore del WP6 del Progetto "BOUNCE: Predicting Effective Adaptation to Breast Cancer to Help Women to BOUNCE Back"
2016 - 2019	AIRC IG 2016 coordinatore del Task 4 del Progetto dal titolo "Unveiling potentially actionable mechanisms of acquired endocrine resistance in breast cancer patients".
2013 - 2016	AIRC IG 2013 N.14069 Coordinatore del clinical task del Progetto dal titolo: "Study of the molecular mechanisms mediating the development of brain metastasis in breast cancer "
2010 - 2015	Team Leader EC-FP7 p-medicine - Grant Agreement no. 270089 Titolo: "From data sharing and integration via Virtual Physiological Human (VPH) models to personalized medicine".
2008 - 2011	RF-INN-2008-1142520 Scientific coordinator of the participation unit, progetto dal titolo: "Resistance to bevacizumab in patients with relapsing glioblastoma".

## ATTIVITA' DI CONSULENZA SCIENTIFICA

2017	Grant Reviewer, Breast Cancer Now, UK
1995-1996	Membro del GRUPPO DI LAVORO "LINEE GUIDA INERENTI L'USO DI PRODOTTI DI TERAPIA GENICA: GUIDA AI PRODUTTORI E AGLI UTILIZZATORI" PRESIDENZA DEL CONSIGLIO DEI MINISTRI - COMITATO NAZIONALE PER LA BIOSICUREZZA E LE BIOTECNOLOGIE

### *Partecipazione a gruppi di Ricerca Nazionali ed Internazionali*

2019 - oggi	Vice-Chair of the Executive of the Scientific Committee of the International Breast Cancer Study Group (IBCSG)
2019 - oggi	Scientific Advisory Council, Breast International Group (BIG), Committee Member
2015 - oggi	Scientific Advisory Council, International Breast Cancer Study Group (IBCSG), Committee Member
2015- oggi	Membro del WG (Working Group) ACC (Alleanza Contro il Cancro)/Neuroncologia

### *Ruoli in Riviste Scientifiche*

2010 - oggi	Editorial Board Member, <i>ecancermedicalsecience</i>
2010 - oggi	Reviewer per numerose riviste, tra cui: <i>Nature Clinical Cancer Reviews</i> , <i>Annals of Oncology</i> , <i>Breast Cancer Research and Treatment</i> , <i>Breast Cancer Research</i> , <i>Clinical Breast Cancer</i> , <i>British Journal of Cancer</i> , <i>European Journal of Cancer</i> , <i>Breast Cancer Research</i> , <i>Critical Review in Hematology-Oncology</i> , <i>The Lancet Oncology</i>

**Alcune partecipazioni negli ultimi 10 anni in qualità di relatore invitato a congressi e convegni di interesse nazionale e internazionale**

2020	Invited Speaker, Best of ASCO ASCO20 Virtual, Milano, IT “Breast Cancer - Metastatic Setting”
2020	Responsabile Scientifico, CORSO WEBINAR Il carcinoma mammario in epoca Covid: L’esperienza della Divisione di Senologia Medica IEO, Milano, IT
2019	Invited Speaker, 3° Hangzhou Xianghu International Breast cancer symposium, Hangzhou, China “The Clinical Practice for ABC Patients in MBC-ABC4”
2018	Invited Speaker, 6th International Meeting on Metronomic Chemotherapy in Oncology Grand Rapids, MI, USA. Keynote presentation “Metronomic chemotherapy for breast cancer: clinical results”.
2017	Invited Speaker, XIX Congresso Nazionale di Oncologia Medica, AIOM, Roma, IT. “Alopecia in corso di chemioterapia: è proprio necessaria?”
2017	Invited Speaker, South African Oncology Roadshow, Sud Africa, “Optimizing disease control in Metastatic Breast Cancer”
2017	Invited Speaker, Milan Breast Cancer Biannual Conference, Milano, IT. “Support and avoiding alopecia during adjuvant chemotherapy”
2013	Invited Speaker 13th Milan Breast Cancer Conference, Milano, Italia, “Extended adjuvant therapy in ERpositive disease: balancing costs and benefit”
2011	Invited Speaker 13th Milan Breast Cancer Conference, Milano, Italia, “Metronomic therapies”

**Affiliazioni a Società Scientifiche Nazionali ed Internazionali**

- Società Italiana di Oncologia Medica (AIOM)
- American Society for Clinical Oncology (ASCO)
- Breast International Group (BIG)
- International Breast Cancer Study Group (IBCSG)

**ATTIVITA' DIDATTICA**

2015- Oggi	Docenza presso il Corso di Master (II° livello) in Farmacia e Farmacologia Oncologica, Università degli Studi di Milano, Dipartimento di Scienze Farmacologiche e Biomolecolari
2014 -2015	Docenza presso il Corso di Master (I livello) in “Infermieristica Oncologica”, Dipartimento di Scienze della Salute, Università degli Studi di Milano
2017 - Oggi	Conseguimento dell’Abilitazione Scientifica Nazionale ai sensi dell’articolo. 16 della Legge 240/2016 per il settore Concorsuale 06/D3, Malattie del Sangue, Oncologia e Reumatologia, Settore Scientifico Disciplinare MED/06, Oncologia Medica
2019 - Oggi	Membro del comitato scientifico della International School of Metronomic ( <a href="http://www.internationalschoolmetronomic.com">www.internationalschoolmetronomic.com</a> )
2020 - oggi	Svolge il ruolo di "tutor" nei confronti del personale in formazione (medici specializzandi).

## Pubblicazioni:

Scopus Author ID:8847473300

Sum of the Times Cited	3330
h-index	29

Publons

Sum of the Times Cited	4027
Average Citations per Item	32,7
h-index	30

Web of Science ResearcherID G-8848-2011

Sum of the Times Cited	3096
Average Citations per Item	24,18
h-index	28

1. Magbanua MJ, Hendrix LH, Hyslop T, Barry WT, 4, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge A, Pierga JY, Fehm T, Vidal-Martínez J, Mavroudis D, Garcia-Saenz JA, Stebbing J, Gazzaniga P, Manso L, Zamarchi R, Antelo ML, De Mattos-Arruda L, Generali D, Caldas C, Munzone E, Dirix L, Delson AL, Burstein H, Qadir M, Ma C, Scott JH, Bidard FC, Park JW, Rugo HS. Serial analysis of circulating tumor cells identifies four prognostic groups for novel risk-stratification in metastatic breast cancer (CALGB 40502/NCCTG N063H) (Alliance). *J Natl Cancer Inst.* 2020 Aug 8:djaa113. doi: 10.1093/jnci/djaa113. Online ahead of print.
2. Montagna E, Canello G, Pagan E, Bagnardi V, Munzone E, Dellapasqua S, Viale G, Mazzarol G, Veronesi P, Galimberti V, Santomauro G, Colleoni M. Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy. *Breast.* 2020 Jul 24;53:138-142. doi: 10.1016/j.breast.2020.07.003. Online ahead of print.
3. Iorfida M, Mazza M, Munzone E. Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives. *Breast Cancer (Dove Med Press).* 2020 Mar 18;12:45-56. doi: 10.2147/BCTT.S196240. eCollection 2020.
4. Viale G, Munzone E. Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched disease. *Breast.* 2019 Nov;48 Suppl 1:S49-S52. doi: 10.1016/S0960-9776(19)31123-3.
5. Munzone E, Pagan E, Bagnardi V, Mazzocco K. Reply to Comments on: "Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp cooling system in early breast cancer patients treated with anthracyclines." *Br J Cancer.* 2019 Oct;121(9):806. doi: 10.1038/s41416-019-0577-4.
6. Schmid S, Klingbiel D, Aebi S, Goldhirsch A, Mamot C, Munzone E, Nolè F, Oehlschlegel C, Pagani O, Pestalozzi B, Rochlitz C, Thürlimann B, von Moos R, Weder P, Zaman K, Ruhstaller T. Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. *BMC Cancer.* 2019 Sep 10;19(1):902. doi: 10.1186/s12885-019-6105-3.
7. Munzone E, Bagnardi V, Campennì G, Mazzocco K, Pagan E, Tramacere A, Masiero M, Iorfida M, Mazza M, Montagna E, Canello G, Bianco N, Palazzo A, Cardillo A, Dellapasqua S, Sangalli C, Pettini G, Pravettoni G, Colleoni M, Veronesi P. Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines. *Br J Cancer.* 2019 Aug;121(4):325-331. doi: 10.1038/s41416-019-0520-8.
8. Cazzaniga ME, Biganzoli L, Cortesi L, De Placido S, Donadio M, Fabi A, Ferro A, Generali D, Lorusso V, Milani A, Montagna E, Munzone E, Orlando L, Pizzuti L, Simoncini E, Zamagni C, Pappagallo GL; "Metronomic Chemotherapy in Advanced Breast Cancer" Study Group. Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future? *Onco Targets Ther.* 2019 Apr 23;12:2989-2997. doi: 10.2147/OTT.S189163. eCollection 2019.
9. Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolè F, Gisbert-Criado R, Mavroudis D, Grisanti S, Giuliano M, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Cabel L, van Laere SJ, Meier-Stiegen F,

- Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Generali D, Cappelletti MR, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Darrigues L, Reis-Filho JS, Gerratana L, Michiels S, Bidard FC, Pantel K. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. *Crit Rev Oncol Hematol*. 2019 Feb;134:39-45. doi: 10.1016/j.critrevonc.2018.12.004. Epub 2018 Dec 19. Review.
10. Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. *J Clin Oncol*. 2019 Mar 1;37(7):559-569. doi: 10.1200/JCO.18.01010. Epub 2019 Jan 16.
  11. Dellapasqua S, Gray KP, Munzone E, Rubino D, Gianni L, Johansson H, Viale G, Ribi K, Bernhard J, Kammler R, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Regan MM, Goldhirsch A, Colleoni M; International Breast Cancer Study Group. Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. *J Clin Oncol*. 2019 Feb 10;37(5):386-395. doi: 10.1200/JCO.18.00296. Epub 2018 Dec 27.
  12. Cazzaniga ME, Munzone E, Bocci G, Afonso N, Gomez P, Langkjer S, Petru E, Pivot X, Sánchez Rovira P, Wysocki P, Torri V. Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project. *Adv Ther*. 2019 Feb;36(2):381-406. doi: 10.1007/s12325-018-0844-4. Epub 2018 Dec 18.
  13. Montagna E, Bagnardi V, Cancelli G, Sangalli C, Pagan E, Iorfida M, Mazza M, Mazzarol G, Dellapasqua S, Munzone E, Goldhirsch A, Colleoni M. Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial. *Breast Care (Basel)*. 2018 Jul;13(3):177-181. doi: 10.1159/000487630.
  14. Munzone E, Colleoni M. Optimal management of luminal breast cancer: how much endocrine therapy is long enough? *Ther Adv Med Oncol*. 2018 Jun 18;10:1758835918777437. doi: 10.1177/1758835918777437.
  15. Cazzaniga ME, Munzone E, Montagna E, Pappagallo G. Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists? *Expert Rev Anticancer Ther*. 2018 Aug;18(8):805-814. doi: 10.1080/14737140.2018.1489244.
  16. Munzone E, Gray KP, Fumagalli C, Guerini-Rocco E, Láng I, Ruhstaller T, Gianni L, Kammler R, Viale G, Di Leo A, Coates AS, Gelber RD, Regan MM, Goldhirsch A, Barberis M, Colleoni M. Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. *Breast Cancer Res Treat*. 2018 Jul;170(2):351-360. doi: 10.1007/s10549-018-4767-1.
  17. Palazzo A, Dellapasqua S, Munzone E, Bagnardi V, Mazza M, Cancelli G, Ghisini R, Iorfida M, Montagna E, Goldhirsch A, Colleoni M. Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer. *Clin Breast Cancer*. 2018 Aug;18(4):328-335. doi: 10.1016/j.clbc.2018.01.010.
  18. Richichi C, Fornasari L, Melloni GEM, Brescia P, Patanè M, Del Bene M, Mustafa DAM, Kros JM, Pollo B, Pruneri G, Sciandivasci A, Munzone E, DiMeco F, Pelicci PG, Riva L, Pelicci G. Mutations targeting the coagulation pathway are enriched in brain metastases. *Sci Rep*. 2017 Jul 26;7(1):6573. doi: 10.1038/s41598-017-06811-x.
  19. Montagna E, Palazzo A, Maisonneuve P, Cancelli G, Iorfida M, Sciandivasci A, Esposito A, Cardillo A, Mazza M, Munzone E, Lai A, Goldhirsch A, Colleoni M. Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial. *Cancer Lett*. 2017 Aug 1;400:276-281. doi: 10.1016/j.canlet.2017.01.027. Epub 2017 Jan 26.
  20. Munzone E, Colleoni M. Metronomics in the neoadjuvant and adjuvant treatment of breast cancer. *Cancer Lett*. 2017 Jan 16. pii: S0304-3835(17)30026-5.

21. Pagani O, Klingbiel D, Ruhstaller T, Nolè F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C, Munzone E, Pestalozzi B, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, Moos RV, Zaman K, Goldhirsch A; Swiss Group for Clinical Cancer Research (SAKK). Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99. *Ann Oncol*. 2016 Dec 19. pii: mdw622. doi: 10.1093/annonc/mdw622.
22. Pruneri G, Gray KP, Vingiani A, Viale G, Curigliano G, Criscitiello C, Láng I, Ruhstaller T, Gianni L, Goldhirsch A, Kammler R, Price KN, Cancelli G, Munzone E, Gelber RD, Regan MM, Colleoni M. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. *Breast Cancer Res Treat*. 2016 Jul;158(2):323-31. doi: 10.1007/s10549-016-3863-3.
23. Aurilio G, Sandri MT, Pruneri G, Zorzino L, Botteri E, Munzone E, Adamoli L, Facchi G, Cullurà D, Verri E, Rocca MC, Zurrida S, Iacovelli R, Nolè F. Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer. *Future Oncol*. 2016 Sep;12(17):2001-8. doi: 10.2217/fon-2016-0081.
24. Galimberti V, Taffurelli M, Leonardi MC, Aristei C, Trentin C, Cassano E, Pietribiasi F, Corso G, Munzone E, Tondini C, Frigerio A, Cataliotti L, Santini D. Surgical resection margins after breast-conserving surgery: Senonetwork recommendations. *Tumori*. 2016 Jun 2;2016(3):284-9. doi: 10.5301/tj.5000500. Review.
25. Raimondi S, Botteri E, Munzone E, Cipolla C, Rotmensz N, DeCensi A, Gandini S. Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis. *Int J Cancer*. 2016 Feb 24. doi: 10.1002/ijc.30062.
26. Cazzaniga ME, Camerini A, Addeo R, Nolè F, Munzone E, Collovà E, Del Conte A, Mencoboni M, Papaldo P, Pasini F, Saracchini S, Bocci G. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development. *Future Oncol*. 2016 Feb;12(3):373-87. doi: 10.2217/fon.15.306. Epub 2015 Nov 19.
27. Munzone E, Giobbie-Hurder A, Gusterson BA, Mallon E, Viale G, Thürlimann B, Ejlertsen B, MacGrogan G, Bibeau F, Lelkaitis G, Price KN, Gelber RD, Coates AS, Goldhirsch A, Colleoni M; International Breast Cancer Study Group and the BIG 1-98 Collaborative Group. Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. *Ann Oncol*. 2015 Dec;26(12):2442-9. doi: 10.1093/annonc/mdv391. Epub 2015 Sep 19.
28. Colleoni M, Munzone E. Picking the optimal endocrine adjuvant treatment for pre-menopausal women. *Breast*. 2015 Nov;24 Suppl 2:S11-4. doi: 10.1016/j.breast.2015.07.004. Epub 2015 Aug 4.
29. Munzone E, Colleoni M. Clinical overview of metronomic chemotherapy in breast cancer. *Nat Rev Clin Oncol*. 2015 Nov;12(11):631-44. doi: 10.1038/nrclinonc.2015.131. Epub 2015 Aug 4. Review.
30. Colleoni M, Munzone E. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer. *Drugs*. 2015 Aug;75(12):1311-21. doi: 10.1007/s40265-015-0433-7.
31. Gorini A, Mazzocco K, Gandini S, Munzone E, McVie G, Pravettoni G. Development and psychometric testing of a breast cancer patient-profiling questionnaire. *Breast Cancer (Dove Med Press)*. 2015 Jun 1;7:133-46. doi: 10.2147/BCTT.S80014. eCollection 2015.
32. Aurilio G, Bagnardi V, Nolè F, Pruneri G, Graffeo R, Petit JY, Cullurà D, Martella S, Locatelli M, Iera M, Rey P, Curigliano G, Rotmensz N, Munzone E, Goldhirsch A. Outcome of Immediate Breast Reconstruction in Patients With Nonendocrine-Responsive Breast Cancer: A Monoinstitutional Case-Control Study. *Clin Breast Cancer*. 2015 Mar 24. pii: S1526-8209(15)00073-7. doi: 10.1016/j.clbc.2015.03.009.
33. Ferrucci PF, Minchella I, Mosconi M, Gandini S, Verrecchia F, Cocorocchio E, Passoni C, Pari C, Testori A, Coco P, Munzone E. Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study. *Melanoma Res*. 2015 Jun;25(3):239-45. doi: 10.1097/CMR.0000000000000146.

34. Aurilio G, Bagnardi V, Graffeo R, Nolè F, Petit JY, Locatelli M, Martella S, Iera M, Rey P, Curigliano G, Rotmensz N, Munzone E, Goldhirsch A. Does immediate breast reconstruction after mastectomy and neoadjuvant chemotherapy influence the outcome of patients with non-endocrine responsive breast cancer? *Anticancer Res.* 2014 Nov;34(11):6677-83.
35. Bouche G, André N, Banavali S, Berthold F, Berruti A, Bocci G, Brandi G, Cavallaro U, Cinieri S, Colleoni M, Curigliano G, Di Desidero T, Eniu A, Fazio N, Kerbel R, Hutchinson L, Ledzewicz U, Munzone E, Pasquier E, Graciela Scharovsky O, Shaked Y, Stërba J, Villalba M, Bertolini F. Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. *Ecancermedalscience.* 2014 Sep 9;8:463. doi: 10.3332/ecancer.2014.463.
36. Munzone E, Bagnardi V, Rotmensz N, Sporchia A, Mazza M, Pruneri G, Intra M, Sciandivasci A, Gentilini O, Luini A, Viale G, Veronesi P, Colleoni M. Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer. *Breast Cancer Res Treat.* 2014 Aug;146(3):573-82. doi: 10.1007/s10549-014-3043-2. Epub 2014 Jul 10.
37. Montagna E, Canello G, Dellapasqua S, Munzone E, Colleoni M. Metronomic therapy and breast cancer: a systematic review. *Cancer Treat Rev.* 2014 Sep;40(8):942-50. doi:10.1016/j.ctrv.2014.06.002. Epub 2014 Jun 18.
38. Munzone E. Highlights from the Ninth European Breast Cancer Conference, Glasgow, 19-21 march 2014. *Ecancermedalscience.* 2014 May 6;8:426. doi: 10.3332/ecancer.2014.426
39. Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, Goldhirsch A, Munzone E, De Vita F, Nolè F. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases.. *Ann Oncol.* 2014 May;25 Suppl 1:i10. doi: 10.1093/annonc/mdl066.8.
40. Iorfida M, Bagnardi V, Rotmensz N, Munzone E, Bonanni B, Viale G, Pruneri G, Mazza M, Cardillo A, Veronesi P, Luini A, Galimberti V, Goldhirsch A, Colleoni M. Outcome of Male Breast Cancer: A Matched Single-Institution Series. *Clin Breast Cancer.* 2014 Mar 1. pii: S1526-8209(14)00033-0. doi: 10.1016/j.clbc.2014.02.008.
41. Bidard FC, Peeters DJ, Fehm T, Nolè F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga JY, Michiels S. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. *Lancet Oncol.* 2014 Apr;15(4):406-14. doi: 10.1016/S1470-2045(14)70069-5. Epub 2014 Mar 11.
42. Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, Adamoli L, Munzone E, Sciandivasci A, De Vita F, Goldhirsch A, Nolè F. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. *Eur J Cancer.* 2013 Nov 21. pii: S0959-8049(13)00904-0. doi: 10.1016/j.ejca.2013.10.004
43. Colleoni M, Munzone E. Extended adjuvant chemotherapy in endocrine non-responsive disease. *Breast.* 2013 Aug;22 Suppl 2:S161-4. doi: 10.1016
44. Munzone E, Curigliano G, Colleoni M. Tailoring adjuvant treatments for the individual patient with luminal breast cancer. *Hematol Oncol Clin North Am.* 2013 Aug;27(4):703-14, vii-viii. doi: 10.1016/j.hoc.2013.05.012.
45. Botteri E, Munzone E, Rotmensz N, Cipolla C, De Giorgi V, Santillo B, Zanelotti A, Adamoli L, Colleoni M, Viale G, Goldhirsch A, Gandini S. Therapeutic effect of B-blockers in triple-negative breast cancer postmenopausal women. *Breast Cancer Res Treat.* 2013 Aug;140(3):567-75. doi: 10.1007/s10549-013-2654-3.



46. Munzone E, Casali C, Aurilio G, Botteri E, Perin A, Pelicci G, Brescia P, Sciandivasci A, Adamoli L, Viale G, Dimeco F. Outcome and clinico-biological characteristics of advanced breast cancer patients with surgically resected brain metastases: a multidisciplinary approach. *Ecancermedicalscience*. 2013 Apr 18;7:309.
47. Botteri E, Munzone E, Intra M, Bagnardi V, Rotmensz N, Bazolli B, Montanari B, Aurilio G, Sciandivasci A, Esposito A, Pagani G, Adamoli L, Viale G, Nolè F, Goldhirsch A. Role of breast surgery in T1-3 breast cancer patients with synchronous bone metastases. *Breast Cancer Res Treat*. 2013 Feb;138(1):303-10.
48. Aurilio G, Monfardini L, Rizzo S, Sciandivasci A, Preda L, Bagnardi V, Disalvatore D, Pruneri G, Munzone E, Della Vigna P, Renne G, Bellomi M, Curigliano G, Goldhirsch A, Nolè F. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. *Acta Oncol*. 2013 Jan 17.
49. Munzone E, Botteri E, Sandri MT, Esposito A, Adamoli L, Zorzino L, Sciandivasci A, Cassatella MC, Rotmensz N, Aurilio G, Curigliano G, Goldhirsch A, Nolè F. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. *Clin Breast Cancer*. 2012 Oct;12(5):340-6. doi: 10.1016/j.clbc.2012.07.001.
50. Aurilio G, Munzone E, Botteri E, Sciandivasci A, Adamoli L, Minchella I, Esposito A, Cullurà D, Curigliano G, Colleoni M, Goldhirsch A, Nolè F. Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report. *Breast J*. 2012 Sep;18(5):470-4. doi: 10.1111/j.1524-4741.2012.01278.x. Epub 2012 Jul 25.
51. Esposito A, Munzone E, Bagnardi V, Adamoli L, Sciandivasci A, Cullurà D, Goldhirsch A, Nolè F. Are there benefits in routine clinical practice of continuing trastuzumab after progression for metastatic breast cancer patients? *Anticancer Drugs*. 2012 Nov;23(10):1089-98.
52. Munzone E, Botteri E, Esposito A, Sciandivasci A, Franchi D, Pruneri G, Rotmensz N, Curigliano G, Adamoli L, Bocciolone L, Goldhirsch A, Nolè F. Outcome and clinical-biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases. *Ann Oncol*. 2012 Apr 29.
53. Munzone E, Botteri E, Sciandivasci A, Curigliano G, Nolè F, Mastropasqua M, Rotmensz N, Colleoni M, Esposito A, Adamoli L, Luini A, Goldhirsch A, Viale G. Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. *Breast Cancer Res Treat*. 2012 Apr 1.
54. Aurilio G, Sciandivasci A, Munzone E, Sandri MT, Zorzino L, Cassatella MC, Verri E, Rocca MC, Nolè F. Prognostic value of circulating tumor cells in primary and metastatic breast cancer. *Expert Rev Anticancer Ther*. 2012 Feb;12(2):203-14.
55. Curigliano G, Locatelli M, Fumagalli L, Brollo J, Munzone E, Nolè F, Criscitiello C, Goldhirsch A. Targeting the subtypes of breast cancer: rethinking investigational drugs. *Expert Opin Investig Drugs*. 2012 Feb;21(2):191-204. Epub 2012 Jan 10. Review.
56. E. Munzone, G. Curigliano, H. Burstein, E.P. Winer, A. Goldhirsch. CMF revisited in the 21st century. "Don't bury me 'cause I'm not dead yet." *Annals of Oncology*, 2011 (DOI: 10.1093/annonc/MDR309)
57. Curigliano G, Bagnardi V, Viale G, Fumagalli L, Rotmensz N, Aurilio G, Locatelli M, Pruneri G, Giudici S, Bellomi M, Della Vigna P, Monfardini L, Orsi F, Nolè F, Munzone E, Goldhirsch A. Should liver metastases of breast cancer be biopsied to improve treatment choice? *Ann Oncol*. 2011 Feb 22.
58. E. Munzone, F. Nole, A. Goldhirsch, E. Botteri, A. Esposito, L. Zorzino, G. Curigliano, I. Minchella, L. Adamoli, MC Cassatella, C. Casadio and M.T. Sandri. Changes of HER-2 status in Circulating Tumour Cells (CTCs) compared with the primary tumour in patients during treatment for advanced breast cancer. *Clin Breast Cancer* 2010 Aug (in press)
59. Botteri E, Sandri MT, Bagnardi V, Munzone E, Zorzino L, Rotmensz N, Casadio C, Cassatella MC, Esposito A, Curigliano G, Salvatici M, Verri E, Adamoli L, Goldhirsch A, Nolè F. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. *Breast Cancer Res Treat*. 2009 Dec 6.

60. Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N, Ghisini R, Colleoni M, Munzone E, Veronesi P, Zurrida S, Nolè F, Goldhirsch A. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. *J Clin Oncol*. 2009 Dec 1;27(34):5693-9. Epub 2009 Nov 2.
61. Munzone E, Di Pietro A, Goldhirsch A, Minchella I, Verri E, Cossu Rocca M, Marengi C, Curigliano G, Radice D, Adamoli L, Nolè F. Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report. *Breast*. 2010 Feb;19(1):33-7. Epub 2009 Nov 1.
62. Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M, Nolè F, Munzone E, Salmaggi A, Goldhirsch A, Pelicci PG, Testori A. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemioimmunotherapy in patients with advanced melanoma. *Br J Cancer*. 2009 Jan 13;100(1):28-36.
63. Nolè F, Munzone E, Zorzino L, et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. *Ann Oncol*. 2008 May;19(5):891-7. Epub 2007 Dec 4.
64. Catania C, Medici M, Magni E, Munzone E, et al. Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination. *Ann Oncol*. 2007 Dec;18(12):1969-75. Epub 2007 Sep 9.
65. Sanna G, Franceschelli L, Rotmensz N, Botteri E, Adamoli L, Marengi C, Munzone E, Cossu Rocca M, Verri E, Minchella I, Medici M, Catania C, Magni E, Goldhirsch A, Nolè F. Brain metastases in patients with advanced breast. *Anticancer Res*. 2007 Jul-Aug;27(4C):2865-9.
66. Nole F, Catania C, Munzone E, Rocca A, Verri E, Sanna G, Ascione G, Adamoli L, Zampino MG, Minchella I, Goldhirsch A. Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer. *Clin Breast Cancer*. 2006 Feb;6(6):518-24.
67. Munzone E, Curigliano G, Rocca A, Bonizzi G, Renne G, Goldhirsch A, Nole F. Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. *Breast Cancer Res*. 2006;8(1):R4
68. Nole F, Catania C, Sanna G, Imadalou K, Munzone E, Adamoli L, Longerey B, Blanchot G, Goldhirsch A. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. *Ann Oncol*. 2006 Feb;17(2):322-9.
69. Nole F, Catania C, Sanna G, Imadalou K, Munzone E, Adamoli L, Longerey B, Blanchot G, Goldhirsch A. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. *Ann Oncol*. 2006 May;17(5):750-62.
70. Curigliano G, Spitaleri G, Pietri E, Rescigno M, de Braud F, Cardillo A, Munzone E, Rocca A, Bonizzi G, Brichard V, Orlando L, Goldhirsch A. Breast cancer vaccines: a clinical reality or fairy tale? *Ann Oncol*. 2005 Nov 17
71. Munzone E, Nole F, Sanna G, Goldhirsch A. Response of bilateral choroidal metastases of breast cancer to therapy with trastuzumab. *Breast*. 2005 Oct;14(5):380-3.
72. Curigliano G, Petit JY, Bertolini F, Colleoni M, Peruzzotti G, de Braud F, Gandini S, Giraldo A, Martella S, Orlando L, Munzone E, Pietri E, Luini A, Goldhirsch A. Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery. *Breast Cancer Res Treat*. 2005 Sep;93(1):35-40.
73. Pagani O, Sessa C, Nole F, Munzone E, Crivellari D, Lombardi D, Thurlimann B, Hess D, Graffeo R, Ruggeri M, Longhi S, Goldhirsch A. Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer. *Ann Oncol*. 2005 Oct;16(10):1609-17.

74. Mandala M, Moro C, Ferretti G, Calabro MG, Nole F, Rocca A, Munzone E, Castro A, Curigliano G. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients. *Anticancer Res.* 2001 Jan-Feb;21(1B):585-8.
75. Nole F, Munzone E, Mandala M, Catania C, Orlando L, Zampino MG, Minchella I, Colleoni M, Peruzzotti G, Marrocco E, Goldhirsch A. Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study. *Ann Oncol.* 2001 Jan;12(1):95-100.
76. Munzone E, Nole F, Orlando L, Mandala M, Biffi R, Ciano C, Villa G, Civelli M, Goldhirsch A. Unexpected right phrenic nerve injury during 5-fluorouracil continuous infusion plus cisplatin and vinorelbine in breast cancer patients. *J Natl Cancer Inst.* 2000 May 3;92(9):755.
77. Locatelli M, Colleoni M, Noberasco C, Nole F, Orlando L, Munzone E, Peruzzotti G, Goldhirsch A. Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (CMF regimen) *Ann Oncol.* 1999 Nov;10(11):1394-5.
78. Cinieri S, Orlando L, Cocorocchio E, Munzone E, Catania C, Brunetti C, Rocca A, Martinelli G, Nole F. Prophylaxis of toxic effects on the peripheral venous system associated with intravenous administration of vinorelbine. *Clin Ter.* 1999 May-Jun;150(3):225-9.
79. Nole F, Minchella I, Colleoni M, Orvieto E, Munzone E, de Braud F, Peruzzotti G, Martinelli G, Zampino MG, Catania C, Pizzamiglio M, Veronesi P, Zurrida S, Galimberti V, Goldhirsch A, Veronesi U. Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN). *Ann Oncol.* 1999 Aug;10(8):993-6.
80. De Pas T, De Braud F, Orlando L, Nole F, Munzone E, Zampino MG, Fazio N, Aapro MS, Goldhirsch A. High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? *Ann Oncol* 1998 Aug;9(8): 917-9
81. Hawkins PN, Aprile C, Capri G, Vigano L, Munzone E, Gianni L, Pepys MB, Merlini G. Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. *Eur J Nucl Med.* 1998 Jul; 25(7): 701-708
82. deBraud F, Munzone E, Nolè F, De Pas T, Biffi R, Brienza S, Aapro MS. Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. *Am J Clin Oncol.* 1998 Jun;21(3):279-83. doi: 10.1097/0000421-199806000-00015.
83. Donelli MG, Zucchetti M, Munzone E, D'Incalci M, Crosignani A. Pharmacokinetics of anticancer agents in patients with impaired liver function. *Eur J Cancer.* 1998 Jan;34(1):33-46. doi: 10.1016/s0959-8049(97)00340-7.
84. E. Munzone, F. de Braud, M. De Pas, M. Zimatore et M.S. Aapro. "Le traitement adjuvant des tumeurs du colon et du rectum". *Medicine & Hygiene N.* 2121, 12 Juin 1996; 1216-1222
85. Gianni L., Munzone E., Capri G., Fulfaro F., Tarenzi E., et al. "Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study". *J Clin Oncol* Vol 13(11), 1995; pp. 2688-2699
86. Scaioli-V; Caraceni-A; Martini-C; Palazzini-E; Tarenzi-E; Fulfaro-F; Munzone-E. Visual evoked potentials findings in course of paclitaxel doxorubicin combination chemotherapy. Report of a case. *J-Neurooncol.* 1995; 25(3): 221-5
87. Gianni-L, Munzone-E, Capri-G, Villani-F, Spreafico-C, Tarenzi-E, Fulfaro-F, Caraceni-A, Martini-C, Laffranchi-A, et-al. "Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines". *J-Natl-Cancer-Inst.* 1995 Aug 2; 87(15): 1169-75
88. Gianni L., Capri G., Munzone E., Straneo M. "Paclitaxel efficacy in patients with advanced breast

cancer". Seminars in Oncology Vol 21(5), Suppl 8 (October) 1994; pp. 29-33

89. Capri, E. Munzone, E. Tarenzi, F. Fulfaro, L. Gianni, A. Caraceni, C. Martini, V. Scaioli. "Optic nerve disturbances: a new form of paclitaxel neurotoxicity". J Natl Cancer Inst, Vol 86 (14), July 20, 1994; pp. 1099-1101 (letter)
90. Munzone E., Capri G., Straneo M., Gianni L. "Taxol: the first taxane anticancer agent". Forum 3:658-671, 1993

#### Capitoli di libri

1. E. Munzone. Anti-HER2 Therapies in the Adjuvant and Advanced Disease Setting. In: Veronesi U., Goldhirsch A., Veronesi P., Gentilini O.D., Leonardi M.C. (Eds.), Breast Cancer - Innovation in Research and Management, DOI 10.1007/978-3-319-48848-6, Springer International Publishing 2017; pp 577-592
2. E. Munzone, C. Casali, M. Del Bene, F. Di Meco. Treatment of Central Nervous System Involvement. In: Veronesi U., Goldhirsch A., Veronesi P., Gentilini O.D., Leonardi M.C. (Eds.), Breast Cancer - Innovation in Research and Management, DOI 10.1007/978-3-319-48848-6, Springer International Publishing 2017; pp 763-768.
3. E. Munzone, F. Bertolini, M. Colleoni. Metronomic Chemotherapy in Breast Cancers. In: G. Bocci, G. Francia (eds.), Metronomic Chemotherapy: Pharmacology and Clinical Applications, DOI 10.1007/978-3-662-43604-2\_6, © Springer-Verlag Berlin Heidelberg 2014; pp 93-110
4. E. Munzone. Neoplasie del pancreas endocrino. Trattamento medico. In: Oncologia Chirurgica, U. Veronesi (ed.), pp. 761, Masson, 1998.

Data

05/09/2020

Luogo

Milano